WhatsApp
backNews Article

Glenmark Pharmaceuticals Inc. Launches Authorized Generic Axitinib Tablets in U.S. Market

New 1 mg and 5 mg Axitinib tablets target $538.4 million annual INLYTA® market as of September 2026

Glenmark Pharmaceuticals Inc., USA has launched Authorized Generic Axitinib Tablets (1 mg and 5 mg), an authorized generic of Pfizer's INLYTA®, targeting a U.S. market with annual sales of approximately $538.4 million as of September 2026. This launch marks Glenmark's expansion in oncology generics, enhancing access to affordable medicines in the United States.

3 days ago|GLENMARK-0.00%
Glenmark Pharmaceuticals Limited532296GLENMARKNew Ventures

Glenmark Pharmaceuticals Limited

New Ventures

Glenmark Pharmaceuticals Inc., USA announced the launch of Authorized Generic Axitinib Tablets in 1 mg and 5 mg doses, an authorized generic version of Pfizer’s INLYTA®, addressing a U.S. market with annual sales around $538.4 million as of September 2026.

The launch expands Glenmark's oncology generics portfolio in the United States, providing more affordable treatment options for patients.

According to IQVIA® data, INLYTA® Tablets had U.S. annual sales of approximately $538.4 million in the 12 months ending September 2026.

This product launch is part of Glenmark’s strategy to enhance access to high-quality, affordable medicines in the U.S. healthcare market.

Highlights

  • Authorized Generic Axitinib Tablets launched in 1 mg and 5 mg strengths.
  • Referenced U.S. market for INLYTA® at $538.4 million annual sales (September 2026).
  • Launch announced on November 16, 2026.
  • Product is an authorized generic version of Pfizer’s INLYTA® (axitinib).
  • Glenmark emphasizes commitment to expanding access to medicines in the U.S.

Key Data Snapshot

Product launchedAxitinib Tablets 1 mg and 5 mg
Product typeAuthorized Generic of INLYTA® (axitinib) tablets
Reference marketU.S. annual sales approx. $538.4 million for INLYTA® tablets (12 months ending September 2026)
Launch dateNovember 16, 2026

What happened

  • Glenmark Pharmaceuticals Inc., USA launched authorized generic versions of axitinib tablets (1 mg and 5 mg).
  • The product is an authorized generic of Pfizer’s INLYTA® tablets, used in oncology treatments.

Key details

  • The launch targets the U.S. market where INLYTA® had $538.4 million in annual sales ending September 2026.
  • Glenmark aims to provide affordable, quality medicines and expand patient access in the United States.

Regulatory and governance context

  • INLYTA® is a registered trademark of Pfizer Inc.
  • The launch follows regulatory approvals allowing Glenmark to market the authorized generic product in the U.S.

More News on New Ventures

View all

Latest corporate announcements and market updates in New Ventures.

View all news
Glenmark Pharmaceuticals Inc. Launches Authorized | Stockk News